Bulliard JL, Braendle K, Fracheboud J, Zwahlen M. Breast cancer screening programmes in Switzerland, 2010–2018; 2021.

Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 2000;355:129–34.

Article  PubMed  Google Scholar 

Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. Dan Med Bull. 2011;58:A4246.

PubMed  Google Scholar 

Swiss Medical Board: Systematisches Mammographie-Screening; 2013.

Duffy SW, Chen THH, Smith RA, Yen AMF, Tabar L. Real and artificial controversies in breast cancer screening. Breast Cancer Management. 2013;2:519–28.

Article  CAS  Google Scholar 

Herrmann C, Vounatsou P, Thürlimann B, Probst-Hensch N, Rothermundt C, Ess S. Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies. BMJ Open. 2018;8:e017806.

Article  PubMed  PubMed Central  Google Scholar 

Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72:524–41.

Article  PubMed  Google Scholar 

Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, Zeng H, Zhou J, Wei W. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (London, England). 2021;41:1183–94.

Article  Google Scholar 

Lim ZL, Ho PJ, Khng AJ, Yeoh YS, Ong ATW, Tan BKT, Tan EY, Tan S-M, Lim GH, Lee JA, Tan VKM, Hu J, Li J, Hartman M. Mammography screening is associated with more favourable breast cancer tumour characteristics and better overall survival: case-only analysis of 3739 Asian breast cancer patients. BMC Med. 2022;20:239.

Article  PubMed  PubMed Central  Google Scholar 

Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, Lynge E. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19(Suppl 1):33–41.

Article  PubMed  Google Scholar 

Molassiotis A, Tyrovolas S, Giné-Vázquez I, Yeo W, Aapro M, Herrstedt J. Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and screening programme availability in 130 countries. ESMO open. 2021;6:100111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, Allgood PC, Kearins O, Tappenden N, O’Sullivan E, Lawrence G. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168:98–104.

Article  PubMed  Google Scholar 

de Munck L, Eijkelboom AH, Otten JDM, Broeders MJM, Siesling S. Method of primary breast cancer detection and the disease-free interval, adjusting for lead time. J Natl Cancer Inst. 2023;116:370–8.

Article  PubMed Central  Google Scholar 

Swiss Cancer Regsitries: Description of the legally binding data dictionary for all cancer registries under the new law on cancer registrations; 2019.

Perry N. Guidelines for quality assurance in breast cancer screening and diagnosis. Luxembourg: Office for Official Publications of the European Communities; 2006.

Google Scholar 

Duffy SW, Lynge E, Jonsson H, Ayyaz S, Olsen AH. Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer. 2008;99:1176–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tabár L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, Krusemo UB, Tot T, Smith RA. The Swedish Two-County Trial twenty years later Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38:625–51.

Article  PubMed  Google Scholar 

Marwah N, Batra A, Marwah S, Gupta V, Shakya S, Sen R. Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: a study from North India. J Cancer Res Ther. 2018;14:537–42.

Article  CAS  PubMed  Google Scholar 

Lee J, Lee Y-J, Bae SJ, Baek SH, Kook Y, Cha YJ, Lee JW, Son BH, Ahn SH, Lee HJ, Gong G, Jeong J, Lee SB, Ahn SG. Ki-67, 21-gene recurrence score, endocrine resistance, and survival in patients with breast cancer. JAMA Netw Open. 2023;6:e2330961.

Article  PubMed  PubMed Central  Google Scholar 

Herrmann C, Morant R, Walser E, Mousavi M, Thürlimann B. Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects. BMC Cancer. 2021;21:229.

Article  PubMed  PubMed Central  Google Scholar 

Jay M, Creelman B, Baliski C. Patient reported outcomes associated with surgical intervention for breast cancer. Am J Surg. 2020;219:816–22.

Article  PubMed  Google Scholar 

Shapiro S, Goldberg JD, Hutchison GB. Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol. 1974;100:357–66.

Article  CAS  PubMed  Google Scholar 

Cox B, Sneyd MJ. Bias in breast cancer research in the screening era. Breast (Edinburgh, Scotland). 2013;22:1041–5.

Article  PubMed  Google Scholar 

Schumann L, Hadwiger M, Eisemann N, Katalinic A. Lead-time corrected effect on breast cancer survival in Germany by mode of detection. Cancers. 2024;16:1326.

Article  PubMed  PubMed Central  Google Scholar 

Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS. Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst. 2015;107:djv014.

Article  PubMed  PubMed Central  Google Scholar 

Ellison LF, Saint-Jacques N. Five-year cancer survival by stage at diagnosis in Canada. Health Rep. 2023;34:3–15.

PubMed  Google Scholar 

Wilkinson AN, Billette J-M, Ellison LF, Killip MA, Islam N, Seely JM. the impact of organised screening programs on breast cancer stage at diagnosis for Canadian women Aged 40–49 and 50–59. Curr oncol (Toronto, Ont). 2022;29:5627–43.

Google Scholar 

He W, Eriksson L, Törnberg S, Strand F, Hall P, Czene K. Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening. BMC Med. 2019;17:24.

Article  PubMed  PubMed Central  Google Scholar 

Aarts MJ, Voogd AC, Duijm LEM, Coebergh JWW, Louwman WJ. Socioeconomic inequalities in attending the mass screening for breast cancer in the south of the Netherlands–associations with stage at diagnosis and survival. Breast Cancer Res Treat. 2011;128:517–25.

Article  CAS  PubMed  Google Scholar 

Pokora RM, Büttner M, Schulz A, Schuster AK, Merzenich H, Teifke A, Michal M, Lackner K, Münzel T, Zeissig SR, Wild PS, Singer S, Wollschläger D. Determinants of mammography screening participation-a cross-sectional analysis of the German population-based Gutenberg Health Study (GHS). PLoS ONE. 2022;17:e0275525.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feller A, Schmidlin K, Bordoni A, Bouchardy C, Bulliard J-L, Camey B, Konzelmann I, Maspoli M, Wanner M, Clough-Gorr KM. Socioeconomic and demographic disparities in breast cancer stage at presentation and survival: a Swiss population-based study. Int J Cancer. 2017;141:1529–39.

Article  CAS  PubMed  Google Scholar 

Jolidon V, de Prez V, Bracke P, Bell A, Burton-Jeangros C, Cullati S. Revisiting the effects of organized mammography programs on inequalities in breast screening uptake: a multilevel analysis of nationwide data from 1997 to 2017. Front Public Health. 2022;10:812776.

Article  PubMed  PubMed Central  Google Scholar 

Sandoval JL, Theler J-M, Cullati S, Bouchardy C, Manor O, Gaspoz J-M, Guessous I. Introduction of an organised programme and social inequalities in mammography screening: a 22-year population-based study in Geneva, Switzerland. Prev Med. 2017;103:49–55.

Article  PubMed  Google Scholar 

Duffy SW, Tabár L, Yen AM-F, Dean PB, Smith RA, Jonsson H, Törnberg S, Chen SL-S, Chiu SY-H, Fann JC-Y, Ku MM-S, Wu WY-Y, Hsu C-Y, Chen Y-C, Svane G, Azavedo E, Grundström H, Sundén P, Leifland K, Frodis E, Ramos J, Epstein B, Åkerlund A, Sundbom A, Bordás P, Wallin H, Starck L, Björkgren A, Carlson S, Fredriksson I, et al. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer. 2020;126:2971–9.

Article  PubMed  Google Scholar 

Smith RA, Duffy SW, Yen AM-F, Tabár L, Lin AT-Y, Chen SL-S, Hsu C-Y, Dean P, Chen TH-H. Beneficial effect of repeated participation in breast cancer screening upon survival. JCO. 2023;41:552.

Article  Google Scholar 

Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, Hübner J. Breast cancer incidence and mortality before and after implementation of the German mammography screening program. Int J Cancer. 2020;147:709–18.

Article  CAS  PubMed  Google Scholar 

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000–2012. JAMA. 2018;319:154–64.

Article  PubMed  PubMed Central  Google Scholar 

Abrahamsson L, Isheden G, Czene K, Humphreys K. Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies. Stat Methods Med Res. 2020;29:374–95.

Article  PubMed  Google Scholar 

The benefits and harms of breast cancer screening: an independent review. Lancet (London, England) 2012, 380:1778–1786